Virtual Event
Date: June 30, 2021
1:30pm EDT
Scientists, medical researchers, marketers, entrepreneurs, enthusiasts, thinkers, and developers of psychedelic products are invited to attend the Microdose Psychedelic Capital: June 2021, a virtual investment conference live streaming on Wednesday, June 30, 2021.
This virtual platform showcases a wonderful opportunity for companies, businesses, and heads of commercial as well as non-profit initiatives to meet and reach out to the length and breadth of industry leaders of the psychedelic medicine arena. Eminent leaders and passionate environmentalists are invited as speakers and share their insights, keynotes and ideas on the present status, growth and development of psychedelic drugs and plant-based formulations.
Companies like Gwella Mushrooms will be showcasing their portfolio, and explain the amazing life-changing benefits of mushrooms to humans and their environmental sustainability. Co-founder and CEO, Peter Reitano, has over a decade of experience in working with top cannabis companies. The company is in the process of exploring how the amalgamation of psychedelic mushrooms into wellness formulations can benefit the mind, body, and spirit.
The conference will subsequently play host to a number of corporate presentations, including:
- ST Biosciences, a global phytopharmaceutical company involved in the research, development, cultivation, processing and commercialization of pharmaceutical and medicinal cannabis products.
- Return Health, whose focus is on the psychedelic medicine dementia initiative.
- Negev Capital, a Psychedelic Medical Intervention Investment Fund will host an exciting roundtable symposium that will explore the intersection between the science of psychedelic mood enhancing actions, and the strategic drug development decisions that are being made in advance of the science.
The roundtable features: Edward Sellers, MD, PhD, FRCPC, FACP, Scientific advisory chair at Diamond Therapeutics & Professor Emeritus, Pharmacology and Toxicology, Medicine and Psychiatry at the University of Toronto; Carol Routledge, Chief Scientific and Medical Officer at Small Pharma; Dr. Gideon Shapiro Ph.D, Vice President of Discovery at Bright Minds; and is moderated by Negev Capital partners Stuart Seidman and Ken Belotsky.
All ticket holders to the event will get access to free recordings for life that they can check in their free time. On purchasing a ticket, all attendees will receive access to the event platform through a link received in their email. The event can be easily accessed on a mobile device. However, to avail all the features of the app, it is recommended that users run the application on their computer devices.
This networking avenue holds tremendous opportunities for professionals to build relationships and get access to pre-IPO investment opportunities. They will also gain knowledge and get know-how with the latest development and innovations in the psychedelic industry. Plant-based investor from diverse backgrounds from all over the globe will attend the event, offering discussions on the latest techniques of cultivation, maintenance, and the roadblocks encountered in the sale and distribution of psychedelic medicine.
To know more about the event, please visit
https://ibn.fm/TsvGC.
About Microdose Psychedelic Insights
Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, original, evidence-based content, strategy and community. We enable and empower society at large to make better, more mindful decisions about psychedelics and its intersection with healthcare, medicine and personal growth. We work with the industry’s most influential stakeholders, some of the world’s best-known brands and an unrivalled network of scientists, researchers, analysts, innovators, investors and advisors.
About Psychedelic Capital
This online event programming is dedicated to providing investment grade information for the nascent psychedelic sector and presents a curated group of CEOs, financial experts, thought leaders and investment luminaries from around the globe. Presentations are 30 minutes in length, with 10 minutes always allocated to a one-on-one Q&A session with the audience. Psychedelic Capital features the top companies, latest IPOs, newest opportunities and deepest insights into the emerging psychedelic space.
